Exagen Inc. (Nasdaq: XGN) announced select preliminary unaudited financial results for Q4 and full year 2025. Revenue for Q4 was $16M to $17M, with a year-over-year growth of 17% to 24%. Full year revenue was $66M to $67M, a 19% to 20% increase over 2024. AVISE CTD volume was 136,000 to 137,000 with a TTM ASP of $441 to $445. Year-end cash and cash equivalents were $32M, a $10M increase over 2024. The company reported record revenue, ASP expansion, test volume growth, and a strong cash position.

Exagen CEO, John Aballi, expressed satisfaction with the company’s strong performance in 2025, highlighting significant revenue growth driven by volume and ASP expansion. Despite challenges in the second half of the year, Exagen strengthened its scientific and commercial teams and launched enhancements to the AVISE platform. The company’s cash position and strategy allow for continued investment in innovation and advancing autoimmune disease care standards.

Exagen provided select preliminary unaudited financial results for the year ended December 31, 2025. The company’s financial closing procedures are not yet complete, and final results may vary. Exagen specializes in autoimmune diagnostics, offering testing solutions for conditions like lupus and rheumatoid arthritis. Forward-looking statements caution that actual results may differ due to inherent business risks, regulatory factors, and market acceptance. Contact Jeff Black, CFO, for more information.

Read more at GlobeNewswire: Exagen Inc. Announces Select Preliminary 2025 Financial